Esprit BTK Post-Approval Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 200 participants.

Also called NCT06656364

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06656364
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Hong Kong SAR China, New Zealand, United Arab Emirates (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06656364. Allocation not applicable; no masking; primary purpose treatment. Start 2024-10-21 (actual); primary completion 2027-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Esprit BTK Post-Approval Study
Acronym
EspritBTKPAS
Condition
Chronic Limb-Threatening Ischemia
Intervention (Device)
Esprit BTK System
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct06656364
Content hash
58ac242407d49a8bbc93c3e73dbd0a4bfeac783c0ced535e987d7c67122beaea